• Jorge Navarro-Pérez, Salvador Peiró, Francisco Brotons-Muntó, Emilio López-Alcina, Arcadio Real-Romaguera, and en nombre del Grupo de trabajo del Programa de Formación e Investigación en Hiperplasia Benigna de Próstata de la Comunidad Valenciana.
• Centro de Salud Salvador Pau, Instituto de Investigación Sanitaria INCLIVA, Valencia, España. Electronic address: jorge.navarro@uv.es.
• Aten Primaria. 2014 May 1; 46 (5): 231-7.

ObjectiveTo assess quality of care indicators for benign prostatic hyperplasia (BPH), and to evaluate their strengths and weaknesses for incorporation into health information systems.DesignStructured expert meeting, using procedures adapted from the nominal group techniques and the Rand consensus method.SettingValencian School of Health Studies.Participants And/Or ContextsForty panellists (74% doctors, 70% from primary care settings) with experience in the management of BPH from 15 departments of the Valencia Health Agency.MethodThree workshops were held simultaneously (examination and diagnosis, drug therapy, and appropriateness and results), and the 15 quality indicators selected by the coordination group were assessed.ResultsEleven of the 15 indicators scored in the range of high relevance. The 5 best rated were: the use of alpha-blockers + 5-alpha reductase inhibitor from certain severity level, digital rectal examination in the initial assessment, follow-up with the International Prostate Symptoms Score (IPSS), the rate of urgent catheterization in Hospital Accident & Emergency Units, initial assessment with the IPSS and the use of alpha-blockers prior to catheter removal for acute retention of urine.ConclusionsSome of the assessed indicators can be useful for incorporation into health information systems.Copyright © 2013 Elsevier España, S.L. All rights reserved.

15 keywords...

hide…